IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma

ClinicalTrials.gov ID: NCT01850524

Public ClinicalTrials.gov record NCT01850524. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 21, 2026, 8:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to provide continued access to ixazomib and/or lenalidomide to participants who are continuing to have clinical benefit and to continue collecting relevant safety data to monitor safety in participants with Newly Diagnosed Multiple Myeloma (NDMM) who are not eligible for stem cell transplant.

Study identification

NCT ID: NCT01850524
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Enrollment: 705 participants

Conditions and interventions

Conditions

Multiple Myeloma

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 29, 2013 (Actual)
Primary completion: Dec 2, 2019 (Actual)
Completion: Jun 24, 2022 (Actual)
Last update posted: Jul 21, 2023

2013 – 2022

United States locations

U.S. sites: 78
U.S. states: 29
U.S. cities: 78

Facility	City	State	ZIP	Site status
Not listed	Birmingham	Alabama	—	—
Not listed	Chandler	Arizona	—	—
Not listed	Tucson	Arizona	—	—
Not listed	Little Rock	Arkansas	—	—
Not listed	Anaheim	California	—	—
Not listed	Corona	California	—	—
Not listed	Fountain Valley	California	—	—
Not listed	Fullerton	California	—	—
Not listed	Irvine	California	—	—
Not listed	La Jolla	California	—	—
Not listed	Mission Hills	California	—	—
Not listed	Oakland	California	—	—
Not listed	Riverside	California	—	—
Not listed	San Diego	California	—	—
Not listed	San Jose	California	—	—
Not listed	San Leandro	California	—	—
Not listed	Santa Clara	California	—	—
Not listed	South San Francisco	California	—	—
Not listed	Vallejo	California	—	—
Not listed	Denver	Colorado	—	—
Not listed	Fort Collins	Colorado	—	—
Not listed	Hartford	Connecticut	—	—
Not listed	Plainville	Connecticut	—	—
Not listed	Fort Myers	Florida	—	—
Not listed	Jacksonville	Florida	—	—
Not listed	Miami	Florida	—	—
Not listed	Miami Beach	Florida	—	—
Not listed	West Palm Beach	Florida	—	—
Not listed	Atlanta	Georgia	—	—
Not listed	Marietta	Georgia	—	—
Not listed	Honolulu	Hawaii	—	—
Not listed	Iowa City	Iowa	—	—
Not listed	Sioux City	Iowa	—	—
Not listed	Louisville	Kentucky	—	—
Not listed	Shreveport	Louisiana	—	—
Not listed	Baltimore	Maryland	—	—
Not listed	Towson	Maryland	—	—
Not listed	Burlington	Massachusetts	—	—
Not listed	Worcester	Massachusetts	—	—
Not listed	Ann Arbor	Michigan	—	—
Not listed	Lansing	Michigan	—	—
Not listed	Southfield	Michigan	—	—
Not listed	Duluth	Minnesota	—	—
Not listed	Minneapolis	Minnesota	—	—
Not listed	Rochester	Minnesota	—	—
Not listed	Bridgeton	Missouri	—	—
Not listed	Kansas City	Missouri	—	—
Not listed	Little Silver	New Jersey	—	—
Not listed	Albuquerque	New Mexico	—	—
Not listed	Farmington	New Mexico	—	—
Not listed	Las Cruces	New Mexico	—	—
Not listed	Buffalo	New York	—	—
Not listed	Lake Success	New York	—	—
Not listed	New York	New York	—	—
Not listed	Poughkeepsie	New York	—	—
Not listed	Cincinnati	Ohio	—	—
Not listed	Cleveland	Ohio	—	—
Not listed	Tulsa	Oklahoma	—	—
Not listed	Eugene	Oregon	—	—
Not listed	Portland	Oregon	—	—
Not listed	Hershey	Pennsylvania	—	—
Not listed	Pittsburgh	Pennsylvania	—	—
Not listed	Scranton	Pennsylvania	—	—
Not listed	Charleston	South Carolina	—	—
Not listed	Cookeville	Tennessee	—	—
Not listed	Nashville	Tennessee	—	—
Not listed	Austin	Texas	—	—
Not listed	Galveston	Texas	—	—
Not listed	San Antonio	Texas	—	—
Not listed	Temple	Texas	—	—
Not listed	Tyler	Texas	—	—
Not listed	Christiansburg	Virginia	—	—
Not listed	Richmond	Virginia	—	—
Not listed	Everett	Washington	—	—
Not listed	Seattle	Washington	—	—
Not listed	Spokane	Washington	—	—
Not listed	Vancouver	Washington	—	—
Not listed	Yakima	Washington	—	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 69 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01850524, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jul 21, 2023 · Synced Oct 21, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT01850524 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →